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CD80 Costimulation Is Required for Th2 Cell Cytokine
Production But Not for Antigen-Specific Accumulation and
Migration into the Lung1
Nicola L. Harris,* Melanie Prout,* Robert J. Peach,† Barbara Fazekas de St. Groth,‡ and
Franca Ronchese2*
The CD28 ligands CD80 and CD86 are expressed on APC, and both provide costimulatory function. However, the reason for the
expression of two separate CD28 ligands remains unclear. We have previously shown that blockade of CD80 costimulation by
Y100F-Ig, a CTL-associated Ag-4 (CTLA4)-Ig mutant that does not bind CD86, inhibits the development of lung inflammatory
immune responses, but does not affect blood eosinophilia or Ab production. Each of those responses was inhibited by treatment
with CTLA4-Ig, which binds both CD80 and CD86. To clarify the mechanism underlying these observations we have developed
a model of lung inflammation using adoptively transferred CD41 T cells expressing a Va111Vb31 transgenic TCR specific for
I-Ek and moth cytochrome c. Treatment with Y100F-Ig inhibited the induction of lung eosinophilia in adoptively transferred mice.
However, Y100F-Ig did not detectably affect the accumulation of Ag-specific T cells at the site of peptide deposit or in the draining
lymphoid tissues. Acquisition of an activated phenotype and expression of adhesion molecules required for migration into the lung
were modestly affected. Importantly, treatment with Y100F-Ig diminished the ability of T cells to produce the cytokines IL-4 and
IL-5 following intranasal challenge with Ag. All the responses examined were severely inhibited by treatment with CTLA4-Ig. We
conclude that T cells require CD80 costimulation for the optimal production of IL-5 following intranasal administration of Ag.
Decreased IL-5 production is the most likely explanation for the diminished airway eosinophilia observed. The Journal of
Immunology, 2001, 166: 4908–4914.
T cell activation requires a signal delivered via interac-tion of the TCR with specific Ag on MHC moleculesand a costimulatory signal. The most fully character-
ized costimulatory signal is mediated by the binding of CD80
and CD86 on APC to their receptor CD28 on T cells (1). Al-
though CD80 and CD86 are only distantly related (2), they
show similar equilibrium binding to CD28 (3). Both molecules
also serve as ligands for a second receptor on T cells, CTLA4,
which appears to deliver inhibitory signals to T cells (4). CD80
and CD86 do not appear to be functionally redundant and may
have distinct roles in the regulation of T cell immunity (5).
However, the exact mechanisms by which CD80 and CD86
could differentially affect T cell activation are not known.
We have previously investigated the role of CD80 costimulation
during in vivo T cell responses using a mutant form of CTLA4-Ig,
Y100F-Ig. Y100F-Ig and CTLA4-Ig bind equally well to CD80,
but the binding of Y100F-Ig to CD86 is undetectable (6). Con-
sequently, Y100F-Ig can be used to selectively block CD80
costimulation. In a model of chicken OVA-induced airway eo-
sinophilia, we have shown that treatment with Y100F-Ig sup-
pressed eosinophil and, to a lesser extent, lymphocyte infiltra-
tion into the lung of OVA-challenged mice, but had no effect on
systemic blood eosinophilia or Ab production (6, 7).
There are several possible explanations for the ability of
Y100F-Ig to suppress OVA-induced lung inflammation. Y100F-Ig
treatment may limit the activation and/or clonal expansion of Ag-
specific T cells in secondary lymphoid tissues, such that responses
in the lung can no longer be induced. Alternatively, CD80 block-
ade may result in altered regulation of the adhesion marker ex-
pression or the chemokine production necessary for the migration
of CD41 Th2 cells into the lungs of airway-challenged mice.
Lastly, CD41 Th2 cells may be able to migrate into the lungs of
airway-challenged mice, but CD80 blockade may prevent T cell
activation at this site, resulting in decreased local IL-5 and cyto-
kine production.
We have developed a new model of Ag-induced lung eosino-
philia mediated by peptide-specific T cells expressing a transgenic
TCR. Using this model we can identify the T cells responsible for
mediating airway inflammation by specific mAbs and investigate
the effect of Y100F-Ig treatment on peptide-induced T cell acti-
vation and migration in vivo. This has enabled us to clarify the
mechanism by which Y100F-Ig suppresses lung inflammatory re-
sponses while leaving systemic eosinophilia and Ag-specific Ab
production intact.
Materials and Methods
Mice
All mice were bred and maintained at the animal facility of the Wellington
School of Medicine. B10.A mice were originally obtained from The Jack-
son Laboratory (Bar Harbor, ME) and maintained by brother 3 sister mat-
ing. The 2I line 5C.C7 transgenic mice (8, 9) were backcrossed to B10.A
mice and maintained by breeding transgenic males to B10.A females. The
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TCR used to generate the 5C.C7 transgenic strain was derived from the
cytochrome c-specific T cell clone 5C.C7. These cells are specific for pi-
geon cytochrome c fragment 81–104 and I-Ek, but proliferate more vigor-
ously when stimulated with peptide fragment 81–103 from the tobacco
horn worm moth cytochrome c (MCC)3 (10, 11). All animal experimental
procedures used in this study were approved by the Wellington School of
Medicine animal ethics committee and were conducted in accordance with
the guidelines of the University of Otago (Dunedin, New Zealand).
Purification of lung lymphocytes, peritoneal cells, and PBLs
Mice used for the preparation of lung lymphocytes were injected i.p. with
150 U of heparin (Leo Pharmaceutical Products, Denmark) and sacrificed.
The lower vena cava was severed, and lungs were perfused via the heart
right ventricle with ;5 ml of PBS to remove circulating blood. Minced
lung tissue was incubated for 30 min in complete IMDM containing 2.4
mg/ml collagenase type II (Life Technologies, Auckland, New Zealand)
and 0.1% DNase I (Sigma, St. Louis, MO). Complete IMDM consisted of
IMDM (Sigma) with 5% FCS (Life Technologies), 2 mM glutamine (Sig-
ma), 1% penicillin-streptomycin (Sigma), and 5 3 1025 M 2-ME (Sigma).
Remaining tissue was then broken down by passage through an 18-gauge
needle, and mononuclear cells were purified by gradient centrifugation
over Lympholyte-M (Cedarlane Laboratories, Ontario, Canada) according
to the manufacturer’s instructions. Macrophages were depleted by cultur-
ing cells on plastic dishes in complete IMDM for 1–2 h at 37°C.
Peritoneal lymphocytes were obtained by sacrificing mice and flushing
;10 ml of PBS into the peritoneal cavity three times. PBLs were purified
by collecting 100 ml of tail blood into 1 ml of Alsevers’ solution (2%
dextrose, 0.4% NaCl, and 0.8% sodium citrate) and lysing RBC by incu-
bation in 0.14 M NH4Cl and 17 mM Tris-HCl for 10–20 min at 37°C.
FACS staining
FACS analysis of lymphocytes was conducted by staining in 96-well
round-bottom plates at 105–106 cells/well for 10–15 min on ice using the
appropriate mAbs diluted in 100 ml of FACS buffer (PBS plus 2% FCS and
0.01% sodium azide). 2.4G2 (10 mg/ml) was used to inhibit FcgRII-me-
diated uptake. Flow cytometric analysis was performed on a FACSort
(Becton Dickinson, Mountain View, CA) using CellQuest software.
Reagents and mAbs
CTLA4-Ig, Y100F-Ig, and L6-Ig were purified from culture medium of
stably transfected Chinese hamster ovary cells as previously described (6).
Anti-CD4 (GK1.5) was grown from hybridoma culture supernatant and
conjugated to FITC or biotin. Anti-Va11-FITC, anti-Vb3-PE, anti-Vb3-
biotin, anti-CD49d-PE, anti-CD44-PE, anti-CD62L-PE, anti-CD80-FITC,
anti-CD86-PE, and streptavidin-FITC, -PE, and -Cy-Chrome were all ob-
tained from PharMingen (San Diego, CA).
Ag-induced airway inflammation
The protocol for induction of OVA-dependent airway inflammation has
been described previously (6). For the adoptive transfer model, cell sus-
pensions were prepared from lymph nodes of 5C.C7 mice, and the per-
centage of Va11, Vb3 TCR-expressing lymphocytes was determined by
FACS analysis. A total of 3 3 106 Va111Vb31 T cells were injected into
the tail vein of sex-matched B10.A mice in a total volume of 500 ml of
IMDM. Two days later recipient mice were immunized i.p. with 250 mg of
MCC87–103 in 200 ml of alum adjuvant (SERVA, Heidelberg, Germany) on
days 0 and 20 after adoptive transfer. Six days after the last i.p. immuni-
zation, mice were anesthetized by injection of a mixture of ketamine and
xylazine (Phoenix, Auckland, New Zealand) and challenged with 100 mg
of MCC87–103 in 50 ml of PBS by intranasal (i.n.) inoculation. At the
corresponding times, nonimmunized mice received alum adjuvant i.p. and
PBS i.n. Mice were sacrificed at the indicated time points after i.n. chal-
lenge, and cellular infiltration into the airways was determined by bron-
choalveolar lavage (BAL) and differential cell counting as previously
described (6).
Enzyme-linked immunospot (ELISPOT)
Cells were cultured at various dilutions for 6 h at 37°C in 96-well plates
(Nunc, Copenhagen, Denmark) coated with 10 mg/ml anti-CD3 mAb
(2C11) and 20 mg/ml anti-IL-5 mAb (TRFK5), anti-IL-4 mAb (11B11), or
anti-IFN-g mAb (R4-6A2) in the presence of IL-2 (10 U/ml). As a control,
cells were also incubated on plates coated with the capture Ab only. After
the initial 6-h incubation plates were washed thoroughly with PBS-Tween,
then 5 mg/ml biotinylated detection Abs (anti-IL-5 mAb, TRFK4; anti-IL-4
mAb, BVD6-24G2; anti-IFN-g mAb, xMG-D6) were added, and plates
were incubated overnight at 4°C. Washed plates were then incubated with
avidin-alkaline phosphatase conjugate (Sigma) for 1 h at room temperature.
Reactions were developed using 5-bromo-4-chloro-3-indoyl-phosphate
(Sigma) and were stopped by addition of distilled water. The number of
spots was determined by counting under an inverted microscope.
RNA isolation and cDNA preparation.
RNA was isolated from mediastinal lymph node (MLN) and lung using
TRIzol (Life Technologies). The RNA was quantified using GeneQuant,
and 1 mg of total RNA was used in the cDNA synthesis reaction. The
cDNA reaction was conducted for 60 min at 37°C using 200 U of Moloney
murine leukemia virus reverse transcriptase (Life Technologies) and 0.5 mg
of oligo-(dT)12–18 primer (Life Technologies).
Polymerase chain reaction
Primers and probes for IL-4, IL-5, IFN-g, and b2-microglobulin were de-
signed and synthesized as described previously (12). Probes were modified
to incorporate a reporter dye at the 59 end (6-carboxy-fluorescein or tetra-
choloro-6-carboxy-fluorescein) and a quencher at the 39 end (6-carboxy-
tetramethyl-rhodimine). The sequences of the oligonucleotides and PCR
conditions are detailed in the report by Hook et al. (12). PCRs were con-
ducted in an ABI Prism 7700 Sequence Detector (PE Applied Biosystems,
Foster City, CA). Reactions were set up using the TaqMan core reagents
(PE Applied Biosystems) according to the manufacturer’s instructions.
MgCl2 (5 mmol/L) was used in the IL-4, IL-5, IFN-g, and b2-microglobu-
lin reactions. Cycling conditions consisted of 50°C for 2 min, 94°C for 10
min, and then 35 cycles of 94°C for 15 s, 58°C for 30 s, and 72°C for 30 s.
DNA standards were made for each of the cytokines and serially diluted
and included with each PCR. Data were analyzed using ABI Prism Se-
quence Detection System version 1.63 software (PE Applied Biosystems).
All amplifications were performed in duplicate, and the amount of DNA in
the samples was calculated from the standard curve. All results were nor-
malized to b2-microglobulin to compensate for differences in the amount of
cDNA in the samples.
Results
Model of MCC87–103-induced airway eosinophilia
A model of peptide-induced lung eosinophilia was developed us-
ing the adoptive transfer of T cells from 5C.C7 mice (8, 9), which
are transgenic for a Va111Vb31 TCR specific for I-Ek and
MCC87–103 (10, 11).
Initial experiments were conducted to determine the optimal im-
munization conditions for the induction of lung eosinophilia. The
variables examined included the number of adoptively transferred
T cells, the peptide dose, and the number and timing of i.p. im-
munizations. It was found that a large number of adoptively trans-
ferred TCR transgenic T cells induced a good response, but was
associated with occasional lethality at the time of i.n. challenge.
Moreover, i.p. immunizations with larger amounts of peptide and
at longer intervals appeared to yield more substantial and more
reproducible eosinophil infiltration (data not shown). Fig. 1 out-
lines the optimal protocol as determined in those experiments.
Briefly, 3 3 106 5C.C7 T cells expressing the transgenic
Va111Vb31 TCR were adoptively transferred into normal syn-
geneic B10.A mice 2 days before the first immunization. Recipient
mice were immunized i.p. with 250 mg of MCC87–103 in alum
adjuvant on days 0 and 20, and then given an i.n. challenge with
100 mg of MCC87–103 in PBS on day 26. Cellular infiltration into
the airways and lung was determined by BAL. Importantly, no
airway eosinophilia was observed in B10.A mice that were immu-
nized and airway challenged with MCC87–103, but had not received
T cells expressing the transgenic Va111Vb31 TCR, using these
immunizing conditions.
3 Abbreviations used in this paper: MCC, moth cytochrome c; i.n., intranasal(ly);
MLN, mediastinal lymph node; BAL, bronchoalveolar lavage; ELISPOT, enzyme-
linked immunospot; VLA-4, very late Ag 4.
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Treatments with Y100F-Ig and CTLA4-Ig suppress MCC87–103-
induced lung eosinophilia
To determine the effect of Y100F-Ig treatment on MCC87–103-
induced airway eosinophilia B10.A mice were adoptively trans-
ferred with Va111Vb31 T cells from 5C.C7 donors, then immu-
nized with MCC87–103/alum and airway challenged as detailed in
Fig. 1. Mice were treated with i.p. injections of 400 mg of human
or 200 mg of murine CTLA4-Ig, Y100F-Ig, or the control molecule
L6-Ig every 48 h, beginning on the day of the first MCC87–103 i.p.
immunization.
The BAL fluid obtained from mice treated with the isotype con-
trol L6-Ig contained high numbers of eosinophils and lympho-
cytes. Treatment with CTLA4-Ig completely abrogated eosinophil
and lymphocyte infiltration into the BAL fluid of MCC87–103-chal-
lenged mice (Fig. 2). Treatment with Y100F-Ig decreased the
number of eosinophils in the BAL 3- to 5-fold on days 1, 3, and 5
after i.n. challenge (Fig. 2), but did not alter MCC87–103-induced
lymphocyte infiltration into the BAL (Fig. 2). Although there was
some variability in the MCC87–103-induced eosinophilia, the sup-
pressive effect of Y100F-Ig treatment was statistically significant
over all time points using ANOVA of log data ( p 5 0.0001).
These data indicate that CD80 costimulation is required for the
development of MCC87–103-induced lung eosinophilia. Therefore,
the inhibitory effect of Y100F-Ig on lung eosinophilia is not lim-
ited to the OVA system in C57BL/6 mice (6), but applies also to
lung eosinophilia mediated by TCR transgenic T cells.
Treatment with Y100F-Ig does not alter the accumulation of
Va111Vb31 T cells in the secondary lymphoid tissues or at the
site of Ag deposit
A possible explanation for the observation that Y100F-Ig can sup-
press airway eosinophilia is that CD80 costimulation is required
for optimal activation and/or clonal expansion of Ag-specific T
cells following i.p. immunization. Alternatively, CD80 blockade
may suppress lung eosinophilia by altering T cell responses fol-
lowing the i.n. challenge of sensitized mice. To distinguish be-
tween these possibilities, the activation and accumulation of T
cells expressing Va111Vb31 TCR were determined at different
times after the second i.p. immunization and after the i.n.
challenge.
After the second i.p. immunization with MCC87–103 in alum, a
considerable accumulation of Va111Vb31 cells was observed in
the spleen and peritoneal cavity of immunized mice compared with
nonimmunized controls (Fig. 3A). A detectable, but smaller, ac-
cumulation of Va111Vb31 T cells was also observed in the
lymph nodes of immunized mice (data not shown). Treatment with
Y100F-Ig had no effect on the number of Va111Vb31 T cells that
accumulated in the spleen or peritoneal cavity (Fig. 3A). In con-
trast, treatment with CTLA4-Ig abrogated MCC87–103-induced ac-
cumulation of Va111Vb31 cells at both sites (Fig. 3A). There-
fore, these data do not support the possibility that Y100F-Ig
treatment alters the clonal expansion or site-specific accumulation
of Ag-reactive T cells following i.p. immunization.
To investigate the alternative possibility that Y100F-Ig treat-
ment may affect the T cell response after i.n. challenge with
MCC87–103, we examined the accumulation of Va111Vb31 T
cells in the MLN, lung, and BAL fluid following i.n. challenge
with MCC87–103 peptide. As shown in Fig. 3B, treatment with
FIGURE 1. Protocol of immunization for the induction of lung eosin-
ophilia by MCC87–103. Normal B10.A mice were injected with 3 3 106
Va111Vb31 T cells from 5C.C7 mice and immunized as outlined. Cel-
lular infiltration into the lung was determined by collecting BAL fluid and
performing differential cell counts on stained cytospins. FIGURE 2. Treatment with Y100F-Ig inhibits lung eosinophilia in
MCC87–103-immunized and airway-challenged mice. Normal B10.A mice
were injected with T cells from 5C.C7 TCR transgenics, then immunized
and airway challenged as detailed in Fig. 1, or were left nonimmunized
(3). Mice were treated throughout the experiment with CTLA4-Ig (E),
Y100F-Ig (L), or the control molecule L6-Ig (M) every 48 h, beginning on
the day of the first i.p. immunization. Mice were sacrificed, and differential
cell counts were made on BAL fluid collected at the indicated time points
after the i.n. challenge. Values represent the mean number of cells per
milliliter of BAL fluid 6 SE of five individual mice. Values for the non-
immunized group are given for day 3 only. The data shown are from one
representative experiment. Similar results were obtained in three separate
experiments using four to six mice per group.
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Y100F-Ig did not notably alter the MCC87–103-induced accumu-
lation of Va111Vb31 T cells at any of those sites. In contrast,
treatment with CTLA4-Ig inhibited the accumulation of
Va111Vb31 T cells at all sites investigated (Fig. 3B). Thus, these
data do not support the alternative possibility that Y100F-Ig treat-
ment may prevent the specific accumulation of Ag-reactive T cells
following i.n. administration of Ag.
The expression of activation markers was examined on Ag-spe-
cific T cells in the MLN after i.n. challenge with MCC87–103. In
immunized mice, Va111Vb31 T cells expressed significantly de-
creased levels of CD62L (L-selectin) compared with the same cells
in naive 5C.C7 mice, while their expression of CD44 (PgP-1) was
increased (Fig. 4). This phenotype is characteristic of Ag-activated
T cells. Treatment with CTLA4-Ig inhibited almost completely the
progression of Va111Vb31 T cells from the naive to the activated
phenotype (Fig. 4). In contrast, Va111Vb31 T cells in mice
treated with Y100F-Ig clearly showed an activated phenotype in
terms of CD62L and CD44 expression. However, on close exam-
ination the ratio of activated, CD62Llow CD44high, to naive
CD62Lhigh CD44low Va111Vb31 T cells was slightly lower in the
Y100F-Ig group compared with that in the control, L6-Ig-treated
group.
In summary, these data indicate that treatment with Y100F-Ig
does not prevent the activation of Va111Vb31 T cells following
MCC87–103 immunization and airway challenge, but does result in
a slightly less activated phenotype compared with that of control,
L6-Ig-treated mice. The likely outcome of a small change in ac-
tivation marker expression in terms of T cell effector function is
unknown.
FIGURE 3. Treatment with Y100F-Ig does not alter the accumulation
of Va111Vb31 T cells in lymphoid organs or peripheral tissues. Normal
B10.A mice were injected with T cells from 5C.C7 TCR transgenics and
then immunized and airway challenged as detailed in Fig. 1 or were left
nonimmunized (3). Mice were treated throughout the experiment with
CTLA4-Ig (E), Y100F-Ig (L), or L6-Ig (M) every 48 h, beginning on the
day of the first i.p. immunization. Total numbers of Va111Vb31 T cells
were determined for spleen and peritoneal washing on day 3 after the
second i.p. immunization (A) and for MLN, lung, and BAL fluid at the
indicated times after i.n. challenge (B). Values represent the mean number
of cells 6 SE of five individual mice, except for lung and BAL fluid, where
the results from pooled samples are shown. Data from nonimmunized mice
are shown for day 3 only. The data shown are from one representative
experiment. Similar results were obtained in three separate experiments
using four to six mice per group.
FIGURE 4. Treatment with Y100F-Ig has a modest effect on the acti-
vation phenotype of Va111Vb31 T cells in MLN. Normal B10.A mice
were injected with T cells from 5C.C7 TCR transgenics, then MCC87–103
immunized and airway challenged as detailed in Fig. 1. Mice were treated
with CTLA4-Ig, Y100F-Ig, or L6-Ig every 48 h, beginning at the time of
the first immunization. Four days after the i.n. challenge mice were sacri-
ficed, and MLN cells were analyzed for the expression of CD62L and
CD44 using three-color fluorescent staining and FACS analysis. Histogram
plots show Va111Vb31 gated T cells. f, nonstained samples; M, samples
stained with anti-CD62L-PE or anti-CD44-PE mAbs as indicated. The
mean fluorescence intensities for each staining are shown in the top right
corner of each histogram. The data shown are from the pooled cells of five
mice in one representative experiment. Similar results were obtained in
three separate experiments using four to six mice per group.
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Treatment with Y100F-Ig does not prevent the depletion of
Va111Vb31 T cells from peripheral blood following i.n.
challenge with MCC87–103 or expression of integrins involved in
migration into inflammatory sites
The data presented in the previous section demonstrate that treat-
ment with Y100F-Ig did not affect the accumulation of
Va111Vb31 T cells in lymphoid organs and lung after i.p. im-
munization and i.n. challenge with MCC87–103. The expression of
the activation markers CD62L and CD44 was moderately affected.
T cell migration and recruitment can also be examined by de-
termining number of Va111Vb31 T cells in peripheral blood at
various times throughout the MCC87–103 immunization and airway
challenge protocol. Over a large number of experiments we have
observed that i.p. immunization with MCC87–103 in alum results in
an increase in the percentage of Va111Vb31 T cells in peripheral
blood. Va111Vb31 T cells rapidly disappear from the blood fol-
lowing i.n. challenge with MCC87–103 (Fig. 5A), presumably re-
flecting migration of activated T cells into the lung and airways. As
shown in Fig. 5A, treatment with Y100F-Ig did not affect the ac-
cumulation of Va111Vb31 T cells in peripheral blood following
i.p. immunization. Y100F-Ig treatment also did not affect the de-
pletion of Va111Vb31 T cells from peripheral blood following
i.n. challenge with MCC87–103 (Fig. 5A). In contrast, accumulation
of Va111Vb31 T cells in the blood was completely inhibited by
treatment with CTLA4-Ig, preventing further analysis of their
migration.
The integrin very late Ag-4 (VLA-4) is involved in the migra-
tion of activated T cells to inflammatory sites, and anti-VLA-4 Ab
treatment has been shown to block the migration of T cells into the
lungs of allergen-challenged animals (13). Thus, we examined ex-
pression of the VLA-4 a subunit, CD49d, on Va111Vb31 T cells
from i.p. immunized mice. No CD49d-expressing Va111Vb31 T
cells could be demonstrated in the lymph nodes or spleen of im-
munized mice (not shown). In control L6-Ig-treated mice periph-
eral blood Va111Vb31 T cells expressed increased levels of
CD49d compared with Va111Vb31 T cells from naive 5C.C7
transgenic mice (Fig. 5B). Cells expressing high levels of CD49d
were preferentially depleted from blood after i.n. challenge with
MCC87–103 (data not shown). Treatment with Y100F-Ig did not
alter the MCC87–103-induced increase in CD49d expression on
blood Va111Vb31 T cells (Fig. 5B). In contrast, Va111Vb31 T
cells in CTLA4-Ig treated mice expressed only low levels of
CD49d (Fig. 5B), comparable to the levels observed in naive
5C.C7 mice.
Taken together, the data in Fig. 5 indicate that Y100F-Ig treat-
ment does not prevent the emigration of Va111Vb31 T cells from
the blood upon i.n. Ag challenge, nor does it alter their expression
of the integrins required for entry into the lung and airways. These
data support the conclusion in the previous section that Y100F-Ig
treatment does not prevent the homing of Va111Vb31 T cells to
the lungs after i.n. administration of Ag.
Treatment with Y100F-Ig inhibits T cell cytokine production
Local IL-5 production is critical to the development of lung eo-
sinophilia (7, 14). Thus, Y100F-Ig may lower airway eosinophilia
by preventing T cell activation and local IL-5 production following
re-encounter with specific Ag in the lung and airways. We inves-
tigated the effects of L6-Ig, Y100F-Ig, and CTLA4-Ig treatment on
the ability of T cells to produce cytokines following Ag immuni-
zation and airway challenge. However, despite extensive analysis
at different time points after i.n. challenge with MCC87–103 pep-
tide, little cytokine production by Va111Vb31 T cells could be
demonstrated in the lung or lymph node by analysis of ELISPOT
or bulk culture supernatants. We next attempted to determine the
effects of L6-Ig, Y100F-Ig, and CTLA4-Ig treatment on T cell
cytokine production in mice immunized and i.n. challenged with
the whole protein Ag OVA. These experiments were conducted
using B10.A mice that had been immunized and i.n. challenged
with OVA as previously described (6), as this immunization pro-
tocol induces a T cell response in which ex vivo cytokine produc-
tion can be more easily measured. As seen using the MCC87–103-
induced airway eosinophilia model, Y100F-Ig treatment of OVA-
immunized B10.A mice resulted in a reduction of airway
eosinophilia. In contrast, BAL lymphocyte numbers were similar
in the L6-Ig- and Y100F-Ig-treated groups. CTLA4-Ig treatment
FIGURE 5. Treatment with Y100F-Ig does not affect depletion of
Va111Vb31 T cells from the blood or their expression of CD49d. Normal
B10.A mice were injected with T cells from 5C.C7 TCR transgenics, then
MCC87–103 immunized and airway challenged as detailed in Fig. 1. Mice
were treated with CTLA4-Ig (E), Y100F-Ig (L), or L6-Ig (M) every 48 h,
beginning at the time of the first i.p. immunization. A, Depletion of Ag-
specific T cells from the blood following i.n. challenge was examined by
determining the percentage of CD41 peripheral blood T cells that are
Va111Vb31 using fluorescent staining and three-color FACS analysis. B,
Three days after the second i.p. immunization peripheral blood
Va111Vb31 T cells were analyzed for expression of the VLA-4 subunit
CD49d. Histogram plots show Va111Vb31 gated T cells. f, nonstained
samples; M, samples stained with anti-CD49d-PE mAb. The mean fluo-
rescence intensities are shown in the top right corner of each histogram.
The data shown are from the pooled cells of five mice in one representative
experiment. Similar results were obtained in three separate experiments
using four to six mice per group.
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inhibited infiltration of either eosinophils or lymphocytes into the
airways (data not shown).
The numbers of cytokine-producing cells were evaluated using
an ELISPOT assay. Given the short restimulation period required,
we considered that the cytokine production measured by this tech-
nique is likely to reflect cytokine production in vivo. Significant
numbers of lymphocytes producing IL-4 and IL-5 were found in
the lung, airways, and MLN of OVA-immunized and airway-chal-
lenged B10.A mice on day 4 following i.n. challenge (Fig. 6, L6-
Ig-treated group). The numbers of IL-4- and IL-5-producing cells
were reduced in the airways, lung, and MLN of Y100F-Ig-treated
mice and were virtually absent from these tissues in CTLA4-Ig-
treated mice (Fig. 6). The number of IFN-g-producing cells in the
lung and MLN of OVA-immunized and challenged mice did not
differ dramatically from that in nonimmunized mice (Fig. 6). The
numbers of IFN-g-secreting cells found in the BAL fluid were
increased in immunized, L6-Ig-treated mice, and this increase was
reduced by treatment with either Y100F-Ig or CTLA4-Ig (Fig. 6).
However, it is not clear whether the IFN-g produced was derived
from CD41 or CD81 T cells.
To further evaluate cytokine production in Y100F-Ig- and
CTLA4-Ig-treated mice, a quantitative RT-PCR assay was used.
IL-4 mRNA copy number was increased in the MLN and lungs of
immunized L6-Ig-treated mice compared with that in nonimmu-
nized mice (Fig. 7). In parallel with the ELISPOT data, treatment
with either Y100F-Ig or CTLA4-Ig led to a reduction in the pro-
duction of IL-4 mRNA in these tissues (Fig. 7). No IL-5 or IFN-g
could be detected using this assay.
Together, these data suggest that the inhibition of lung eosino-
philia by Y100F-Ig treatment is due to decreased IL-5 production
by specific T cells. Interestingly, this defective T cell cytokine
production in Y100F-Ig-treated mice is not limited to the lung and
airways, but also occurs in the MLN.
Discussion
We have previously shown that CD80 costimulation is necessary
for the induction of airway eosinophilia in immunized mice (6). In
the present study we also show that this finding is not a result of
any defect in the accumulation of Ag-specific T cells at inflamed
sites or in the draining lymphoid tissue. Instead, CD80 blockade
decreased the production of the cytokines IL-4 and IL-5 by specific
T cells following exposure to soluble Ag delivered i.n. This de-
creased cytokine production is likely to result in decreased eosin-
ophilia, as IL-5 production has been shown previously to be crit-
ical for the development of airway eosinophilia (7, 14).
We do not think that these data are in conflict with our previous
findings that Y100F-Ig treatment lowered airway eosinophilia, but
not blood eosinophilia or Ab production, in immunized mice (6).
Rather, these data may simply reflect differences in the level of T
cell cytokine production required for the development of airway
eosinophilia as opposed to the development of peripheral blood
eosinophilia or the provision of T cell help to B cells. For instance,
IL-5 production is reduced, but not lost, in Y100F-Ig treated mice.
Therefore, the amount of Ag-specific IL-5 production occurring
during the immunization and challenge of Y100F-Ig-treated mice
may be adequate for the differentiation and recruitment of eosin-
ophils from the bone marrow, but not for their recruitment from
blood into lung. Likewise, perhaps only a small number of IL-4-
producing T cells are required to deliver help to the limited pool of
Ag-specific B cells responsible for producing OVA-specific IgE. If
FIGURE 6. Treatment with Y100F-Ig decreases the numbers of IL-4-
and IL-5-producing cells in the lung, airways, and MLN of OVA-immu-
nized and airway-challenged mice. Normal B10.A mice were immunized
and airway challenged with OVA as previously described (6). Mice were
treated with CTLA4-Ig, Y100F-Ig, or L6-Ig every 48 h, beginning at the
time of the first immunization. Four days after the i.n. challenge mice were
sacrificed, and BAL fluid, lung, and MLN collected. Cell suspensions were
plated onto microtiter plates coated with capture mAb with anti-CD3 mAb
(f) or without anti-CD3 mAb (M) and cultured for 6 h before revealing
bound cytokines using the appropriate detection mAb. The total number of
cytokine-producing lymphocytes was calculated by multiplying the frac-
tion of cytokine-producing cells by the total number of cells in that tissue.
Data represent the mean 6 range of duplicate measurements from the
pooled cells of four mice in one representative experiment. Similar results
were obtained in three separate experiments using three mice per group.
FIGURE 7. Treatment with Y100F-Ig decreases the amount of IL-4
mRNA found in the MLN and lung of OVA-immunized and airway-chal-
lenged mice. Normal B10.A mice were immunized and airway challenged
with OVA and treated with L6-Ig, Y100F-Ig, or CTLA4-Ig as described in
Fig. 6. RNA was isolated from MLN and lung at 24–48 h after i.n. challenge
using TRIzol. IL-4 mRNA copy numbers were then estimated by real-time
quantitative RT-PCR using the Applied Biosystems Prism 7700 Sequence De-
tector as described in Materials and Methods. b2-Microglobulin expression
was used to normalize samples. Values represent the mean 6 range of dupli-
cate samples taken from pooled tissues of three mice.
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this were the case one would not expect to see a comparable re-
duction in IgE production following a reduction in the numbers of
IL-4-producing T cells.
It is interesting that cytokine production by T cells was de-
creased by CD80 blockade while other T cell functions, such as
clonal expansion and migration into peripheral tissues, appeared
unaffected. This may reflect a unique dependence of Th2 cell dif-
ferentiation and/or Th2 cytokine production on CD80 costimula-
tion. IL-4 and IL-5 cytokine production are considered to be late
events in T cell activation (15), only occurring following a certain
number of cell divisions, and may be more dependent on CD80
costimulation due to the slow kinetics of CD80 up-regulation on
activated APCs (16). In our system, we detected no evidence of
inhibition of T cell division, as similar numbers of Va111Vb31
transgenic T cells were found to accumulate in the lungs and lym-
phoid tissues of L6-Ig and Y100F-Ig-treated mice. However, more
sensitive techniques may be required to reveal small differences in
cell division. It is also possible that CD80-mediated signals are
required for the differentiation of T cells into Th2 independently of
cell division. This possibility is favored by the observation that
expression of adhesion molecules on T cells was modestly, but
detectably, decreased in Y100F-Ig-treated compared with L6-Ig-
treated mice. Lastly, as further discussed below, Y100F-Ig may
simply act by inhibiting the secretion of cytokines by fully differ-
entiated effector T cells. Effector T cells in our model were of the
Th2 type; thus, the inhibitory effect was observed on IL-4 and IL-5
secretion. However, we do not rule out the possibility that a similar
inhibition may be observed on other types of effector T cells and
cytokines. Indeed, we observed that treatment with Y100F-Ig re-
sulted in decreased IFN-g production by BAL lymphocytes in the
present study, and in CD81 T cells following infection with in-
fluenza virus (17).
An alternative explanation for our findings is that CD80 block-
ade may decrease cytokine production following administration of
soluble Ag i.n., but not following administration of Ag in alum
adjuvant i.p. In this case Y100F-Ig treatment would not be ex-
pected to affect the development of blood eosinophilia or the pro-
duction of T cell-dependent Abs following Ag/alum immunization,
but it would lower cytokine production following the administra-
tion of Ag in PBS as for the i.n. challenge. This possibility has not
been directly investigated; however, an obvious explanation for
such a scenario would be that APCs up-regulate CD86 following
challenge with Ag in an adjuvant such as alum, providing adequate
costimulation to the responding T cells even in the absence of
CD80. Conversely, encounter with Ag in PBS may not result in
comparable CD86 up-regulation, deeming the presence of CD80
necessary for adequate costimulation.
Although the lack of IL-5 production by lung T cells is likely to
result in defective eosinophil recruitment, we have not ruled out
the possibility that this could also occur by altered chemokine
production. Many chemokines regulate eosinophil chemotaxis, the
most potent being RANTES and eotaxin (18–20). The major cel-
lular sources of eotaxin are thought to be the epithelium, endothe-
lium, and eosinophils themselves rather than T cells (19, 20). How-
ever, T cells are known to produce the chemokines RANTES and
macrophage inflammatory protein-1a, and this has previously been
shown to be CD28 dependent (21). Although we have not formally
investigated the possibility, it would not be surprising if T cells
that are defective for IL-4 and IL-5 production also fail to produce
relevant chemokines.
In conclusion, we have found that the major effect of blocking
CD80 costimulation on T cell function appears to be in the pro-
duction of cytokines following i.n. challenge with Ag. The lack of
IL-5 production by these T cells is likely to be responsible for the
inhibition of airway eosinophilia seen in Y100F-Ig-treated mice.
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